Longevity · Research Phase
Sirtuin-Activating Peptides
No lawful US pathway
01 · Overview
Sirtuin-activating peptides are a proposed class of compounds intended to enhance the activity of sirtuins, a family of NAD-dependent deacetylases implicated in metabolic regulation and aging. The concept is to mimic or potentiate effects attributed to caloric restriction through pathways involving sirtuin 1.
Small molecule sirtuin activators such as resveratrol have received far more research attention than peptide approaches. No peptide-based sirtuin activator has entered clinical development.
02 · Research summary & key findings
Most evidence linking sirtuin activation to longevity comes from genetic manipulation and small molecule activators in yeast, worms and rodents rather than from peptide therapeutics. A systematic review of mouse studies comparing resveratrol with caloric restriction found that resveratrol-supplemented mice mostly did not show significant reductions in body weight, glucose or insulin, and that resveratrol and caloric restriction often affected molecular targets differently, so the potential of resveratrol to act as a caloric restriction mimetic appears limited (PMID 33271594). Published evidence specifically for peptide-based sirtuin activators was not identified, and no clinical trials have evaluated such peptides in humans.
03 · Regulatory status
Sirtuin-Activating Peptides is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
No lawful pathway today
Sirtuin-Activating Peptides is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 3 FDA-approved compounds in Longevity
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for longevity and healthy ageing?
Sirtuin-Activating Peptides is a research compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on longevity and healthy ageing, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]The Potential of Resveratrol to Act as a Caloric Restriction Mimetic Appears to Be Limited: Insights from Studies in Mice Adv Nutr, 2021. PMID 33271594
Primary literature
- PubMed: "Sirtuin-Activating Peptides"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Sirtuin-Activating Peptides"
Registered interventional and observational studies, including status and phase.
- PubChem: "Sirtuin-Activating Peptides"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Longevity
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.